EligibleTrials

A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine

Recruiting · NCT04965675 · Interventional (participants receive a specific treatment) · Lead sponsor: H. Lundbeck A/S

View the official record on ClinicalTrials.gov →
Migraine

Interventions studied

EptinezumabPlacebo

What this trial is about

To find out if eptinezumab is better than placebo (normal saline solution) in lowering the number of days with migraine in young people ages 12 to 17 with chronic migraine.

Who can take part

Age range
12 Years to 17 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 3
Study type
Interventional (participants receive a specific treatment)

Inclusion criteria

Exclusion criteria

Where it is running

60 locations listed across 15 US states.

Showing 60 of 83 listed sites. See the official record for the complete list.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.